Molecular and Cellular Microbiology (MCM) | Host-Microbe Interaction and Pathogenesis
Microbiol. Biotechnol. Lett. 2021; 49(1): 120-129
https://doi.org/10.48022/mbl.2009.09013
Thanakorn Chaiyaem1, Chulapong Chanta2, and Wisoot Chan-it1*
1Biology Program, Faculty of Science and Technology, Pibulsongkram Rajabhat University, Phitsanulok 65000, Thailand 2Pediatric Unit, Chiangrai Prachanukroh Hospital, Chiang Rai 57000, Thailand
Correspondence to :
Wisoot Chan-it,
wchanit@psru.ac.th
Rotavirus A (RVA) is recognized as a major etiology responsible for the development of acute gastroenteritis in children worldwide. The purpose of the present study was to perform the molecular characterization of RVA. A total of 323 stool specimens collected from hospitalized children with acute gastroenteritis in Chiang Rai, Thailand, in 2016−2018 were identified for G- and P-genotypes through RT-PCR analysis. RVA was more prevalent in 2017−2018 (37.8%) than in 2016−2017 (23.2%). The seasonal peak of RVA occurred from March to April. G3P[8] was predominant in 2016−2017 (90.6%) and 2017−2018 (58.6%). Other genotypes including G1P[8], G8P[8], G9P[8], and mixed infections were also identified. G3P[8] strains clustered together in the same lineage with other novel human equine-like G3P[8] strains previously identified in multiple countries and presented a genotype 2 constellation (G3-P[8]-I2-R2-C2-M2-A2-N2-T2-E2-H2). Several amino acid differences were observed in the antigenic epitopes of the VP7 and VP8* capsid proteins of the equine-like G3P[8] compared with those of the RVA vaccine strains. The homology modeling of the VP7 and VP8* capsid proteins of the equine-like G3P[8] strains evidently exhibited that these residue differences were present on the surface-exposed area of the capsid structure. The emergence of the equine-like G3P[8] strains in Thailand indicates the rapid spread of strains with human and animal gene segments. Continuous surveillance for RVA is essential to monitor genotypes and genetic diversity, which will provide useful information for selecting rotavirus strains to develop a safe and effective RVA vaccine that is efficacious against multiple genotypes and variants.
Keywords: Rotavirus, acute gastroenteritis, epidemiology, genotyping, equine-like G3P[8], homology modeling
Rotavirus A (RVA) is recognized as a major worldwide etiologic agent causing acute gastroenteritis in young children and different animal species. In humans, RVA infection can lead to high morbidity and mortality for patients, who develop severe dehydration, contributing an estimated 215,000 deaths among the children aged < 5 years annually [1]. RVA is classified into the
Genetic diversity of RVA can occasionally evolve through the process of intergenotype reassortment events during co-infection between RVA of human and animal origins, resulting in the increased detections of RVA bearing unusual genotypes. Since 2013, the rapid geographic distribution among human population of unusual equine-like G3 intergenogroup reassortant rotaviruses in association with P[4], P[6], or P[8] have been detected in many countries, including Australia [4−6], Brazil [7−9], Dominican Republic [10], Germany [11], Hungary [12], Indonesia [13−15], Ireland [16], Italy [17], Japan [18−21], Spain [22], Thailand [23, 24], and USA [25]. First surveillance of RVA in Chiang Rai province of Thailand has previously described the finding an emergence of G9P[8] as the predominant genotype in 2015−2016 [23]. In order to continue monitoring of circulating RVA in Chiang Rai, the purpose of the present study was the molecular characterization of RVA in Chiang Rai, Thailand, 2016−2018.
A total of 323 fecal specimens were collected from infants and children with acute gastroenteritis admitted to Chiangrai Prachanukroh Hospital in Chiang Rai, Northern Thailand. The specimen collection period was from March 2016 to February 2018 (a two-year period). The ages of the subjects ranged from neonate up to 5 years old. Acute gastroenteritis was defined as the occurrence of 3 or more episodes of watery or looser than normal stool in a 24 h period before the visit. The specimens were stored at -20℃ until used.
Viral RNAs were extracted from 10% w/v fecal suspensions using Viral Nucleic Acid Extraction Kit II (Geneaid), according to the manufacturer’s instructions. The extracted RNAs were reverse transcribed to synthesize cDNAs by reverse transcription using ReverTra Ace® qPCR-RT Master Mix (Toyobo). RVA was detected by RT-PCR using 5x HOT FIREPol Blend Master Mix (Solis BioDyne) with Beg9/VP7-1′ primer pair, yielding a 395-bp amplicon [26].
RVA-positive samples were G- and P-genotyped by semi-nested multiplex PCR assays. Briefly, the first-round PCR was performed using conserved primers Beg9/End9 or VP7-F/VP7-R for VP7 gene and Con3/Con2 for VP4 gene. The second-round semi-nested multiplex PCR was performed using G-type-specific primers: G1-G4, G9, and G12; and P-type-specific primers: P[4], P[6], and P[8] [27−29]. For untypable samples, multiplexed one-step genotyping method with new G- and P-target specific primers was performed to identify G1−G4, G9, and G12; and P[4], P[6], P[8], P[9], and P[10] [30]. For those samples that still remained untyped were subjected to nucleotide sequencing.
Some of RVA-positive samples that had been successfully typed as G3 by the method mentioned above were selected as representatives for each month for further PCR to confirm whether they were an equine-like G3 genotype using the equine-like G3 specific primers EQG3FWD 5′-CTGCATACGCTAATTCTACACAAGG-3′ and EQG3REV 5′-GATCGTACAAGTAGCCGTAGTAAC-3′, which amplified a 544-bp amplicon of the VP7 gene of the equine-like G3 [4].
G- and P-genotypes were examined by electrophoresis using 1.5% agarose gel, stained with RedSafe™ Nucleic Acid Staining Solution (20000x) (iNtRON Biotechnology, Korea), and observed under UV light.
The 11 genomes of the equine-like G3P[8] strains were partially amplified by PCR using 2x Long Range Master Mix (Biotechrabbit, Germany). Primers used in the amplification were published elsewhere [31]. PCR amplicons were purified using Gel/PCR DNA Fragments Extraction Kit (Geneaid), and then sequenced using Big-Dye Terminator Cycle Sequencing Kit (Applied Biosystems, USA) in an automated ABI Prism 310 Genetic Analyzer (Applied Biosystems). Multiple alignments of nucleotide and amino acid sequences between studied and reference strains were analyzed. Phylogenetic trees, based on the partial nucleotide sequences of VP1 (985 bp), VP2 (918 bp), VP3 (859 bp), VP4 (852 bp), VP6 (848 bp), VP7 (1,052 bp), NSP1 (811 bp), NSP2 (891 bp), NSP3 (870 bp), NSP4 (672 bp), and NSP5 (755 bp), were constructed by the neighbor-joining method in MEGA 7.0. The statistical significance of genetic relationship was estimated by bootstrap resampling analysis (1,000 replications). Nucleotide sequences of the analyzed RVA strains had been submitted to the GenBank under accession number MK161352-MK161391.
Homology modeling of VP7 and VP8* outer capsid proteins were constructed using the G3 VP7 trimer in complex with a neutralizing Fab (PDB: 3FMG) and the VP8* domain from a P[8] VP4 spike-forming protein binding to the secretory H type-1 antigen (PDB: 6HA0) as templates, respectively, using the UCSF Chimera- and ChimeraX-Molecular Modeling systems. Briefly, the BLAST proteins between targets and templates, using the Chimera, demonstrated high amino acid sequence identity of 98% for VP7 and 97% for VP8*, indicating that the 3FMG and the 6HA0 were appropriate templates for generating homology models. For comparative modeling of the VP7, a monomer was first predicted by Chimera interface to Modeller and saved it to a PDB file for 3 copies with different names. The trimer of the VP7 model was then generated by superposition of each monomer model onto each chain in the trimeric structure of 3FMG.PDB1 biological assembly 1 using the program ChimeraX. The comparative VP8* model was only predicted and generated into a monomer form using the same method as above. Finally, the trimer form of constructed VP7 models and the monomer form of VP8* models were visualized by Chimera; amino acid changes present on the exposed-surface area of the outer capsid structures were highlighted and labeled.
The study protocol was conducted according to the approval by the Ethics Committee, Chiangrai Prachanukroh Hospital (CR 0032.102/34017 and CR 0032.102/15688). Parents or caretakers of pediatric patients were described by doctors and nurses about objectives and methods used for laboratory research. Permission for collecting stool specimens directly from diapers and clinical information of the patients was received from their parents who were asked to sign an informed consent. The clinical data included frequency of diarrhea (episodes/ day), vomiting (episodes/day) and body temperature.
RVA was overall detected in 102 of 323 stool specimens (31.6%): 23.2% in 2016−2017 and 37.8% in 2017−2018 (Table 1). Most of the patients with RVA infection were in a 12- to 23-month-old group: 43.8% in 2016−2017 and 34.3% in 2017−2018 (Table 2). Patients under 36 months old or 3 years of age were greatly infected by RVA: 84.4% in 2016−2017 and 92.8% in 2017−2018. RVA was detected for 4 months in 2016−2017 and almost all months in 2017−2018. The seasonal peak occurred during the summer from March to April: 90.7% in 2016−2017 and 70% in 2017−2018 (Table 3).
Table 1 . Detection and distribution of G- and P-genotype combinations of RVA in Chiang Rai, Thailand.
Year | No. of samples | No. of RVA-positive samples (%) | No. of genotypes (%) | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|---|
G1P[8] | G3P[8] | G8P[8] | G9P[8] | G1,G3P[8] | G1,G9P[8] | G3,G9P[8] | ||||
2015-2016 | 270 | 91 (33.7) | 3 (3.3) | 12 (13.2) | - | 72 (79.1) | 2 (2.2) | 1 (1.1) | 1 (1.1) | [23] |
2016-2017 | 138 | 32 (23.2) | - | 29 (90.6) | 1 (3.1) | 2 (6.3) | - | - | - | This study |
2017-2018 | 185 | 70 (37.8) | 7 (10.0) | 41 (58.6) | - | 20 (28.6) | - | - | 2 (2.8) | This study |
Table 2 . Age-related distribution of patients infected with RVA in Chiang Rai, Thailand.
Age group (months) | No. of RVA-positive samples (%) | ||
---|---|---|---|
2016-2017 (n = 32) | 2017-2018 (n = 70) | Total (n = 102) | |
≤5 | 1 (3.1) | 5 (7.1) | 6 (5.9) |
6-11 | 9 (28.1) | 25 (35.7) | 34 (33.3) |
12-23 | 14 (43.8) | 24 (34.3) | 38 (37.3) |
24-35 | 3 (9.4) | 11 (15.7) | 14 (13.7) |
36-47 | 4 (12.5) | 4 (5.7) | 8 (7.8) |
≥48 | 1 (3.1) | 1 (1.4) | 2 (2) |
Table 3 . Monthly distribution of RVA-positive samples in Chiang Rai, Thailand.
Month | No. of RVA-positive samples (%) | ||
---|---|---|---|
2016-2017 (n = 32) | 2017-2018 (n = 70) | Total (%) (n = 102) | |
Mar | 14 (43.8) | 17 (24.3) | 31 (30.4) |
Apr | 15 (46.9) | 25 (35.7) | 40 (39.2) |
May | 1 (3.1) | 7 (10) | 8 (7.8) |
Jun | - | 3 (4.3) | 2 (2) |
Jul | - | 2 (2.9) | 3 (2.9) |
Aug | - | - | - |
Sep | - | 1 (1.4) | 1 (1) |
Oct | - | 5 (7.1) | 5 (4.9) |
Nov | - | 1 (1.4) | 1 (1) |
Dec | - | 5 (7.1) | 5 (4.9) |
Jan | - | - | - |
Feb | 2 (6.3) | 4 (5.7) | 6 (5.9) |
G3P[8] was the predominant genotype: 90.6% in 2016−2017 and 58.6% in 2017−2018. G9P[8] was identified as the second most prevalent genotype in 2017−2018 (28.6%) (Table 1). Other G- and P-genotypes and mixed infections were also identified as summarized in Table 1. Some of the identified G3 samples had been confirmed as the equine-like G3 genotype by PCR: 34.5% (10 of 29 samples) of 2016−2017 and 48.7% (20 of 41 samples) of 2017−2018 (data not shown).
VP7 and VP4 genes of 11 G3P[8] strains as representatives were sequenced and analyzed. Among these 11 samples, 2 strains RVA/Human-wt/THA/2CR29/2016/G3P[8] and RVA/Human-wt/THA/2CR41/2016/G3P[8] were subjected to further nucleotide sequence analysis of their 11 genes. Analysis found that all VP7 and VP4 nucleotide sequences shared high nucleotide identity (99−100%) with each other. Phylogenetic tree showed that the VP7 genes of Chiang Rai G3 strains clustered in the same lineage with other novel equine-like G3 strains recently identified in different countries, including Australia, Brazil, Dominican Republic, Germany, Hungary, Indonesia, Ireland, Italy, Japan, Spain, Thailand, and USA. In contrast, the VP7 genes of the equine-like G3 strains clustered in different lineages with other typical G3 strains detected in the past of Thailand before 2015 (Fig. 1A). Phylogenetic tree of the VP4 genes revealed that all of the 11 P[8] genes clustered in the same P[8] lineage, most closely related to those of the equine-like P[8] strains (Fig. 1B).
Analysis of genomic constellation on the 2 representative strains RVA/Human-wt/THA/2CR29/2016 and RVA/Human-wt/THA/2CR41/2016 resulted in genotype 2 constellation of the backbone genes (G3-P[8]-I2-R2-C2-M2-A2-N2-T2-E2-H2). Phylogenetic trees of the VP1-VP3, VP6, and NSP1-NSP5 genes of the representative strains demonstrated close genetic relatedness with other human equine-like G3P[8] strains (Figs. S1A−S1I).
In an attempt to understand the molecular basis of amino acid differences on an outer capsid VP7 protein and a spike VP8* protein, the antigenic epitopes of the representative equine-like G3 strains were compared with those of RVA vaccine strains. And comparative models of VP7 and VP8* proteins were constructed to demonstrate positions of the amino acid differences. As the results, the equine-like G3 strain represented by RVA/Human-wt/THA/2CR29/2016/G3P[8] contained 14 amino acid differences across the antigenic regions compared with the G1 Rotarix™ vaccine strain (Fig. 2A). When compared with the G3 strain of RotaTeq™ vaccine, 4 amino acid differences were observed: 1 of which occurred in 7-1a region (T87S) and 3 in 7-1b region (N213T, K238D, and D242A). The homology models clearly presented that these amino acid differences were located on the surface-exposed area of the VP7 capsid structure (Fig. 2B).
For VP8* neutralizing epitope comparison, the equinelike P[8] strain had 8 amino acid differences across the antigenic regions compared with the P[8] Rotarix™ vaccine strain (Fig. 3A), containing 8-1: S146G, N150D, S190N, and N196G; and 8-3: N113D, S125N, S131R, and N135D. The equine-like P8] strain comprised 4 amino acid differences: 8-1: S146G, N150S, and D196G; and 8-3: N113D) when compared with the P[8] RotaTeq™ vaccine strain. The VP8* comparative models also demonstrated that all of the amino acid differences were located on surface-exposed area of the spike VP8* protein (Fig. 3B).
Acute gastroenteritis caused by RVA is a primary illness in children under 5 years of age and is considered as an important public health burden in both developing and developed countries. In this study, the follow-up surveillance of RVA was carried out by RT-PCR from diarrheal samples collected from hospitalized infants and children in Chiang Rai, Thailand, 2016−2018. RVA was recognized as the causative agent of the disease for 23.2% in 2016−2017 and 37.8% in 2017−2018 (Table 1), which is consistent with the results of previous reports in Thailand with RVA infection rates ranging from 17.8% to 44.5% [23, 24, 32−42].
Epidemiological reports had found that RVA infection more commonly occurred in children under 3 years of age [23, 32, 43]. In agreement with this, the present results showed a marked tread toward higher rates of infection in children under 3 years of age (90.2%) versus children over 3 years of age (9.8%) with children of the 12- to 23-month-old group being the most frequently affected (Table 2). The lower prevalence in older children could be described as they might develop acquired immunity through previous infection.
The seasonal peak of RVA infection in this surveillance appeared in summer between March and April (Table 3), which is in line with the finding of the previous season 2016−2017 in Chiang Rai [23] and other reports in Thailand [24, 44]. In addition, a different seasonal pattern of RVA infection in Thailand was also observed in rainy season between July and August with high detection rate and number of equine-like G3P[8] strains [24]. Maneekarn & Khamrin [44] has summarized the seasonality of rotavirus gastroenteritis based on epidemiological researches in Thailand, which is in tropical region that rotavirus was detected all-yearround with the peak from November to April of the following year. In contrast to Japan, which is in temperate region, studies of non-hospitalized patients associated with RVA infection found that RVA peaked in spring during March to April, but was lowest during summer from July to August [43]. It has been hypothesized that rotavirus survival is favored by cooler conditions with low humidity in the temperate regions [45], but the smaller seasonal changes in temperature and humidity in some tropical settings compared to temperate ones could make it difficult to study weather as a driver of diarrheal disease, since weather covariates can be highly correlated (e.g., heat and humidity) [46]. In addition, different weather variables can also influence human behavior, sanitation, hygiene practices and the probability of environmental exposures [46]. For example, summer can encourage individuals to have outdoor or social activities, increasing the opportunity of close contact between infected and susceptible individuals, while rainfall can promote individuals to stay indoors. Taken together, seasonal fluctuation of RVA can vary by distinct geographical zones with different weather condition, such as temperature and humidity and can be influenced by other multiple factors, including route of transmission, social behaviors, health practices, methods used to measure infection, and RVA genotypes [44, 45]. Knowledge derived from the seasonal trend of RVA infection in each region can be used to target vaccination program, test efficacy of the vaccine implementation program, and the vaccine itself [47].
Regarding G and P genotyping of RVA, 3 common G-P combinations comprising of G1P[8], G3P[8], and G9P[8] were identified in up to 97% of the studies samples. According to extensive epidemiological studies of RVA infection in Thailand since 2000, G1 is the most frequent genotype, followed by G9 [23, 32−38, 40−42]. RVA G3 emerged as the leading genotype only in 2009−2011 [39]. In this study, interestingly, the distribution pattern of RVA in Chiang Rai has shifted from the previous season from G9P[8] [23] to G3P[8] (Table 1). G3P[8] in this study had similar genetic relatedness with the reassortant equine-like G3P[8] strains that have been detected since 2013 in different countries.
First equine-like G3 strains processing a P[4] were identified in Japan, which exhibited the highest genetic identity with the equine rotavirus strain RVA/Horse-wt/IND/Erv105/2003-05/G3P[X] [21]. The earliest reported novel equine-like G3 strains processing a P[8] were identified in specimens collected from Australia and Thailand in 2013 [4, 19]. This equine-like G3P[8] has spread around the globe with different detection rates in Australia [4−6], Brazil [7−9], Dominican Republic [10], Germany [11], Hungary [12], Indonesia [13−15], Ireland [16], Italy [17], Japan [18−21], Spain [22], Thailand [23, 24], and USA [25]. In the same time, equine-like G3 strains in combination with a P[6] had been examined for the first time in samples collected in 2016 in Indonesia [13, 15]. The findings of equine-like G3 strains combined with various P[4], P[6], and P[8] genotypes indicate the virus diversity and an increased probability of the genome reassortment at the VP4 gene.
In the present study, the equine-like G3P[8] strains, represented by RVA/Human-wt/THA/2CR29/2016 and RVA/Human-wt/THA/2CR41/2016, emerged as the majority RVA gastroenteritis cases. Most recently, equine-like G3P[8] strains with a short RNA pattern, represented by RVA/Human-wt/THA/MS2014-0134/2014/G3P[8] and RVA/Human-wt/THA/DBM2016-096/2016/G3P[8], were detected at a high frequency in other provinces of Thailand, including Bangkok (80.6%), Phuket (78.3%), and Chanthaburi (27.5%) [24]. This reveals that the equine-like G3P[8] appeared to have emerged around the same time in Northern, Middle, Eastern, and Southern Thailand between 2014 to 2018.
Two RVA vaccines (monovalent Rotarix™ RV1: G1P[8] and pentavalent RotaTeq™ RV5: G1, G2, G3, G4, and P[8] have been commercially available since 2011 and are currently added into National Immunization Programs of Thailand since 2019. VP7 and VP8* (a trypsin digestion product of the VP4) contain multiple antigenic epitopes that can induce the production of neutralizing antibodies, which are a main target for vaccine development. Changes or amino acid differences in the antigenic region in these proteins may influence the efficacy of RVA vaccines. In the current survey, the equine-like G3P[8] strains contained many amino acid differences in all antigenic regions compared with the G1, G3, and P[8] strains of RVA vaccines and these amino acid differences were mainly located on the exposed surface of the capsid protein (Figs. 2−3). It has been reported that in Australia the equine-like G3P[8] strains was detected to be more prevalent in areas where Rotarix™ vaccine was being administered, raising the possibility that RVA vaccine pressure may lead to the selection of novel strains [5, 13]. It remains unclear whether the antigenic difference of the equinelike VP7 and VP8* resulted from the selective pressure by the use of RVA vaccines or is sufficiently prominent to obscure the site from recognition by pre-existing antibodies or effect vaccine efficacy in a subtle way. Taken together, considering that the equine-like G3P[8] rotavirus strains containing several amino acid differences has emerged as one of the most prevalent RVA genotypes in some countries, future RVA vaccine candidates containing the equine-like G3P[8] strain would be the vaccine regionally more specific and provide a secured homotypic protective response to the newly emerging equine-like G3P[8] genotype.
Combination of clinical symptoms between the previous survey in Chiang Rai [23] and this study showed that the severity of symptoms in RVA patients with G3P[8] genotype was similar to that in RVA patients with G9P[8] genotype (Table S1). This is consistent with a survey conducted in Indonesia found no difference of the severity of symptoms between patients associated with the quine-like G3P[8] and the typical human RVA G1 and G3 [13]. In contrast to studies conducted in Australia and Japan, equine-like G3P [8] infections resulted in the most episodes of severe gastroenteritis [4, 20].
In conclusion, the emergence of the equine-like G3P [8] strain related to a number of gastroenteritis cases in Thailand, 2016−2018 and other countries indicates the rapid spread of the virus with human and animal gene segments. Information on genetic comparison between the studied strains and the RVA vaccine strains should facilitate the development of a safe and effective RVA vaccine that is efficacious against multiple genotypes and variants. Thus, an important priority is to continue identification of the most common G and P genotypes and genetic diversity after introduction of RVA vaccines into National Immunization Programs of Thailand since 2019.
This study was partially supported by grants-in-aid from Research and Development Institute, Pibulsongkram Rajabhat University, Thailand. The authors gratefully acknowledge pediatric physicians, nurses, and assistants of Pediatric Unit, Chiangrai Prachanukroh Hospital for fecal specimen collection.
The authors have no financial conflicts of interest to declare.
Areerat Manowong, Chulapong Chanta, and Wisoot Chan-it
Microbiol. Biotechnol. Lett. 2022; 50(1): 126-134 https://doi.org/10.48022/mbl.2109.09001Rania Abozahra*, Sarah M. Abdelhamid, Amel G. Elsheredy, Kawther E. Abdulwahab, and Kholoud Baraka
Microbiol. Biotechnol. Lett. 2021; 49(2): 239-248 https://doi.org/10.48022/mbl.2008.08012Abdul Waris, Muhammad Ali, Atta Ullah Khan, Asmat Ali and Abdul Baset
Microbiol. Biotechnol. Lett. 2020; 48(3): 252-266 https://doi.org/10.4014/mbl.2004.04006